Study on Exosome Changes in Patients With Proliferative Diabetic Retinopathy

NCT ID: NCT06198543

Last Updated: 2024-01-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-01-31

Study Completion Date

2025-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Diabetic retinopathy is a common complication of diabetes and one of the leading causes of low vision and blindness in adults. In recent years, the prevalence of diabetes and the incidence of diabetic retinopathy have increased significantly in our country. Epidemiological studies show that the prevalence rate of diabetes in China is 12.8%, and the prevalence rate of DR in adult diabetic patients is 24.7%-37.5%, that is, there are about 3200-48 million DR patients in China, and the patients have a trend of younger people. DR has become a serious public health problem threatening people's lives and health.

At present, it is known that the pathogenesis of DR is related to hypoxia, oxidative stress, inflammation, abnormal expression of cytokines and gene methylation, but the specific pathogenesis has not been fully clarified. Due to the hidden early symptoms of DR, the lack of basic screening conditions in primary medical and health institutions, and the lack of awareness of DR by patients themselves, many DR patients have already appeared serious retinopathy when they seek medical treatment, resulting in irreversible visual function impairment. In addition, the current clinical treatment methods for DR mainly include retinal photocoagulation therapy, intraocular anti-VEGF drug injection and vitrectomy surgery, etc. These methods are aimed at relatively severe diabetic retinopathy, and there is no effective treatment method for early diabetic retinopathy that can prevent or slow down the occurrence and development of DR. Therefore, to further explore the pathogenesis of DR and develop new therapeutic methods has become an urgent problem.

Exosomes are extracellular vesicles secreted by living cells with a diameter of 40-150nm. With a bilayer lipid membrane structure, exosomes contain a variety of biomolecules such as lipids, proteins, nucleic acids, cytokines, and autoantigens, and are important mediators for the transmission of biological information between cells. Almost all cells can secrete exosomes, and exosomes from different cells have different functions. Exosomes transfer their contents to nearby or distant cells and participate in cell growth, angiogenesis, immune regulation and other processes. Previous studies have shown that exosomes secreted by various cells in the retina are present in the vitreous and aqueous humor of patients and play an important role in the pathogenesis of DR. At the same time, exosomes in the systemic circulation of diabetic patients can also reach the retina through the blood circulation, participate in the initiation process of DR And play an important role. At the same time, due to the double-layer lipid membrane structure, exosomes can also target the coated components to specific cells and tissues through biological barriers such as blood-brain and blood-eye, which is expected to become a highly efficient drug delivery route. Therefore, the role of exosomes in DR Treatment has also attracted much attention.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

一、Research Purpose

1. compared the changes of exosomes in intraocular fluid and blood of patients with proliferative diabetic retinopathy and non-diabetic patients.
2. analysed differentially expressed proteins in the exosomes of the two groups of patients using proteomic techniques, laying the foundation for screening possible biomarkers and potential therapeutic targets for the early diagnosis of diabetic retinopathy.

二、Design

1. Subject Population Patients with proliferative diabetic retinopathy and non-diabetic macular epiretinal membrane/macular hole requiring vitrectomy were admitted to the Ophthalmology Department of Xuanwu Hospital, Capital Medical University.
2. Sample Size A total of 60 patients were included in the study.
3. Grouping of Subjects Experimental group: proliferative diabetic retinopathy; Control group: patients with macular epiretinal membranes and macular holes without diabetes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Retinopathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

experimental group

proliferative diabetic retinopathy

No interventions assigned to this group

control group

patients with macular epiretinal membranes and macular holes without diabetes.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age ≥18 years old;
2. Patients diagnosed with PDR by FFA and requiring vitrectomy for treatment;
3. Patients with no history of diabetes and diagnosed with macular anterior membrane or macular hiatus by color fundus photography and OCT;
4. Sign the informed consent form.

Exclusion Criteria

1. Suffering from cancer, immune diseases, infectious diseases and other systemic diseases;
2. Patients with retinal arteriovenous obstruction;
3. Intraocular infection;
4. Patients with uveitis;
5. In patients with high myopia, the equivalent spherical lens was \> -9.0D;
6. Recent history of cerebral infarction, myocardial infarction and other thrombus;
7. Patients with contraindications to surgery.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Xuanwu Hospital, Beijing

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Hang Wu, Master

Role: CONTACT

+8613911993866

Zhen Li, Doctor

Role: CONTACT

+8613581646689

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

wuhang

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.